Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial.
Langrehr
J M
JM
Department of Surgery, Charité, Campus Virchow-Klinikum, Humboldt University-Berlin, Berlin, Germany.
Klupp
J
J
Junge
G
G
Jonas
S
S
Neuhaus
R
R
Bechstein
W O
WO
Neuhaus
P
P
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001424:Bacterial Infections / Q000453:epidemiology; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009181:Mycoses / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology; D011239:Prednisolone / Q000627:therapeutic use; D011446:Prospective Studies; D018805:Sepsis / Q000453:epidemiology; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D011239:Prednisolone; D001379:Azathioprine; D016559:Tacrolimus